Open Access

Inhibition of MCM2 enhances the sensitivity of ovarian cancer cell to carboplatin

  • Authors:
    • Minjie Deng
    • Jiajun Sun
    • Suhong Xie
    • Hui Zhen
    • Yanchun Wang
    • Ailing Zhong
    • Hongqin Zhang
    • Renquan Lu
    • Lin Guo
  • View Affiliations

  • Published online on: July 9, 2019     https://doi.org/10.3892/mmr.2019.10477
  • Pages: 2258-2266
  • Copyright: © Deng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Chemotherapy is widely used for the treatment of ovarian cancer. Since chemotherapy resistance is the major cause of poor prognosis in patients with ovarian cancer, it is important to identify new methods to improve the efficacy of chemotherapy. Minichromosome maintenance complex component 2 (MCM2), which serves an essential role in DNA replication, has been recently identified as a novel proliferation marker with prognostic implications in multiple types of cancer. However, the role of MCM2 in ovarian cancer and its underlying molecular mechanisms remain unclear. Therefore, in the present study, the biological effects of MCM2 were investigated, particularly with respect to DNA damage and repair. In the present study, short hairpin RNA was employed to knockdown MCM2 expression in the A2780 ovarian cancer cell line. The sensitivity of A2780 cells to carboplatin was assessed by cell colony formation assay. The present results suggested that MCM2 knockdown inhibited the proliferation of tumor cells, induced G0/G1 phase arrest and did not exhibit effects on cell apoptosis. However, MCM2 knockdown significantly decreased the colony formation of A2780 cells treated with carboplatin. Furthermore, knockdown of MCM2 together with carboplatin treatment or UV irradiation increased the protein expression level of γ‑H2A histone family member X and p53 compared with control cells. The present data suggested that the increased sensitivity to carboplatin may occur via the p53‑dependent apoptotic response. Additionally, the present results suggested that knockdown of MCM2 may have therapeutic applications in enhancing the efficacy of carboplatin in patients with ovarian cancer.

References

1 

Dahiya N and Morin PJ: MicroRNAs in ovarian carcinomas. Endocr Relat Cancer. 17:F77–F89. 2010. View Article : Google Scholar : PubMed/NCBI

2 

Greenlee RT, Hill-Harmon MB, Murray T and Thun M: Cancer statistics, 2001. CA Cancer J Clin. 51:15–36. 2001. View Article : Google Scholar : PubMed/NCBI

3 

Wright JD, Shah M, Mathew L, Burke WM, Culhane J, Goldman N, Schiff PB and Herzog TJ: Fertility preservation in young women with epithelial ovarian cancer. Cancer. 115:4118–4126. 2009. View Article : Google Scholar : PubMed/NCBI

4 

Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et al: MicroRNA signatures in human ovarian cancer. Cancer Res. 67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI

5 

Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW and Bryson P: Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 14:195–208. 2007. View Article : Google Scholar : PubMed/NCBI

6 

Forsburg SL: Eukaryotic MCM proteins: Beyond replication initiation. Microbiol Mol Biol Rev. 68:109–131. 2004. View Article : Google Scholar : PubMed/NCBI

7 

Lei M: The MCM complex: Its role in DNA replication and implications for cancer therapy. Curr Cancer Drug Targets. 5:365–380. 2005. View Article : Google Scholar : PubMed/NCBI

8 

Bell SP and Dutta A: DNA replication in eukaryotic cells. Annu Rev Biochem. 71:333–374. 2002. View Article : Google Scholar : PubMed/NCBI

9 

Dimitrova DS, Todorov IT, Melendy T and Gilbert DM: Mcm2, but not RPA, is a component of the mammalian early G1-phase prereplication complex. J Cell Biol. 146:709–722. 1999. View Article : Google Scholar : PubMed/NCBI

10 

Mendez J and Stillman B: Perpetuating the double helix: Molecular machines at eukaryotic DNA replication origins. Bioessays. 25:1158–1167. 2003. View Article : Google Scholar : PubMed/NCBI

11 

Parker MW, Botchan MR and Berger JM: Mechanisms and regulation of DNA replication initiation in eukaryotes. Crit Rev Biochem Mol Biol. 52:107–144. 2017. View Article : Google Scholar : PubMed/NCBI

12 

Romanowski P and Madine MA: Mechanisms restricting DNA replication to once per cell cycle: The role of Cdc6p and ORC. Trends Cell Biol. 7:9–10. 1997. View Article : Google Scholar : PubMed/NCBI

13 

Hennessy KM, Lee A, Chen E and Botstein D: A group of interacting yeast DNA replication genes. Genes Dev. 5:958–969. 1991. View Article : Google Scholar : PubMed/NCBI

14 

Gibson SI, Surosky RT and Tye BK: The phenotype of the minichromosome maintenance mutant mcm3 is characteristic of mutants defective in DNA replication. Mol Cell Biol. 10:5707–5720. 1990. View Article : Google Scholar : PubMed/NCBI

15 

Kunnev D, Rusiniak ME, Kudla A, Freeland A, Cady GK and Pruitt SC: DNA damage response and tumorigenesis in Mcm2-deficient mice. Oncogene. 29:3630–3638. 2010. View Article : Google Scholar : PubMed/NCBI

16 

Pruitt SC, Bailey KJ and Freeland A: Reduced Mcm2 expression results in severe stem/progenitor cell deficiency and cancer. Stem Cells. 25:3121–3132. 2007. View Article : Google Scholar : PubMed/NCBI

17 

Yousef EM, Furrer D, Laperriere DL, Tahir MR, Mader S, Diorio C and Gaboury LA: MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation. Mod Pathol. 30:682–697. 2017. View Article : Google Scholar : PubMed/NCBI

18 

de Andrade BA, León JE, Carlos R, Delgado-Azañero W, Mosqueda-Taylor A and de Almeida OP: Expression of minichromosome maintenance 2, Ki-67, and geminin in oral nevi and melanoma. Ann Diagn Pathol. 17:32–36. 2013. View Article : Google Scholar : PubMed/NCBI

19 

Czyzewska J, Guzińska-Ustymowicz K, Pryczynicz A, Kemona A and Bandurski R: Immunohistochemical evaluation of Ki-67, PCNA and MCM2 proteins proliferation index (PI) in advanced gastric cancer. Folia Histochem Cytobiol. 47:289–296. 2009. View Article : Google Scholar : PubMed/NCBI

20 

Guzińska-Ustymowicz K, Pryczynicz A, Kemona A and Czyzewska J: Correlation between proliferation markers: PCNA, Ki-67, MCM-2 and antiapoptotic protein Bcl-2 in colorectal cancer. Anticancer Res. 29:3049–3052. 2009.PubMed/NCBI

21 

Gakiopoulou H, Korkolopoulou P, Levidou G, Thymara I, Saetta A, Piperi C, Givalos N, Vassilopoulos I, Ventouri K, Tsenga A, et al: Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: Relationship with cell cycle regulators and prognostic implications. Br J Cancer. 97:1124–1134. 2007. View Article : Google Scholar : PubMed/NCBI

22 

Scott IS, Heath TM, Morris LS, Rushbrook SM, Bird K, Vowler SL, Arends MJ and Coleman N: A novel immunohistochemical method for estimating cell cycle phase distribution in ovarian serous neoplasms: Implications for the histopathological assessment of paraffin-embedded specimens. Br J Cancer. 90:1583–1590. 2004. View Article : Google Scholar : PubMed/NCBI

23 

Dudderidge TJ, Stoeber K, Loddo M, Atkinson G, Fanshawe T, Griffiths DF and Williams GH: Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res. 11:2510–2517. 2005. View Article : Google Scholar : PubMed/NCBI

24 

Kodani I, Osaki M, Shomori K, Araki K, Goto E, Ryoke K and Ito H: Minichromosome maintenance 2 expression is correlated with mode of invasion and prognosis in oral squamous cell carcinomas. J Oral Pathol Med. 32:468–474. 2003. View Article : Google Scholar : PubMed/NCBI

25 

Feng D, Tu Z, Wu W and Liang C: Inhibiting the expression of DNA replication-initiation proteins induces apoptosis in human cancer cells. Cancer Res. 63:7356–7364. 2003.PubMed/NCBI

26 

McGuire WP III and Markman M: Primary ovarian cancer chemotherapy: Current standards of care. Br J Cancer. 89 (Suppl 3):S3–S8. 2003. View Article : Google Scholar : PubMed/NCBI

27 

Mah LJ, El-Osta A and Karagiannis TC: GammaH2AX: A sensitive molecular marker of DNA damage and repair. Leukemia. 24:679–686. 2010. View Article : Google Scholar : PubMed/NCBI

28 

Cortez D, Glick G and Elledge SJ: Minichromosome maintenance proteins are direct targets of the ATM and ATR checkpoint kinases. Proc Natl Acad Sci USA. 101:10078–10083. 2004. View Article : Google Scholar : PubMed/NCBI

29 

Bates S and Vousden KH: p53 in signaling checkpoint arrest or apoptosis. Curr Opin Genet Dev. 6:12–18. 1996. View Article : Google Scholar : PubMed/NCBI

30 

Gottlieb TM and Oren M: p53 and apoptosis. Semin Cancer Biol. 8:359–368. 1998. View Article : Google Scholar : PubMed/NCBI

31 

Janus F, Albrechtsen N, Dornreiter I, Wiesmüller L, Grosse F and Deppert W: The dual role model for p53 in maintaining genomic integrity. Cell Mol Life Sci. 55:12–27. 1999. View Article : Google Scholar : PubMed/NCBI

32 

Macleod K, Mullen P, Sewell J, Rabiasz G, Lawrie S, Miller E, Smyth JF and Langdon SP: Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res. 65:6789–6800. 2005. View Article : Google Scholar : PubMed/NCBI

33 

Labib K: How do Cdc7 and cyclin-dependent kinases trigger the initiation of chromosome replication in eukaryotic cells? Genes Dev. 24:1208–1219. 2010. View Article : Google Scholar : PubMed/NCBI

34 

Bochman ML and Schwacha A: The Mcm2-7 complex has in vitro helicase activity. Mol Cell. 31:287–293. 2008. View Article : Google Scholar : PubMed/NCBI

35 

Shima N, Alcaraz A, Liachko I, Buske TR, Andrews CA, Munroe RJ, Hartford SA, Tye BK and Schimenti JC: A viable allele of Mcm4 causes chromosome instability and mammary adenocarcinomas in mice. Nat Genet. 39:93–98. 2007. View Article : Google Scholar : PubMed/NCBI

36 

Yang C, Wen Y, Li H, Zhang D, Zhang N, Shi X, Jiang B, Ma X, Yang P, Tang H, et al: Overexpression of minichromosome maintenance 2 predicts poor prognosis in patients with gastric cancer. Oncol Rep. 27:135–142. 2012.PubMed/NCBI

37 

Obermann EC, Went P, Zimpfer A, Tzankov A, Wild PJ, Stoehr R, Pileri SA and Dirnhofer S: Expression of minichromosome maintenance protein 2 as a marker for proliferation and prognosis in diffuse large B-cell lymphoma: A tissue microarray and clinico-pathological analysis. BMC Cancer. 5:1622005. View Article : Google Scholar : PubMed/NCBI

38 

Crevel G, Hashimoto R, Vass S, Sherkow J, Yamaguchi M, Heck MM and Cotterill S: Differential requirements for MCM proteins in DNA replication in Drosophila S2 cells. PLoS One. 2:e8332007. View Article : Google Scholar : PubMed/NCBI

39 

Tsao CC, Geisen C and Abraham RT: Interaction between human MCM7 and Rad17 proteins is required for replication checkpoint signaling. EMBO J. 23:4660–4669. 2004. View Article : Google Scholar : PubMed/NCBI

40 

Oehlmann M, Score AJ and Blow JJ: The role of Cdc6 in ensuring complete genome licensing and S phase checkpoint activation. J Cell Biol. 165:181–190. 2004. View Article : Google Scholar : PubMed/NCBI

41 

Ibarra A, Schwob E and Méndez J: Excess MCM proteins protect human cells from replicative stress by licensing backup origins of replication. Proc Natl Acad Sci USA. 105:8956–8961. 2008. View Article : Google Scholar : PubMed/NCBI

42 

Lei M, Kawasaki Y and Tye BK: Physical interactions among Mcm proteins and effects of Mcm dosage on DNA replication in Saccharomyces cerevisiae. Mol Cell Biol. 16:5081–5090. 1996. View Article : Google Scholar : PubMed/NCBI

43 

Rowles A, Chong JP, Brown L, Howell M, Evan GI and Blow JJ: Interaction between the origin recognition complex and the replication licensing system in Xenopus. Cell. 87:287–296. 1996. View Article : Google Scholar : PubMed/NCBI

44 

Stoeber K, Tlsty TD, Happerfield L, Thomas GA, Romanov S, Bobrow L, Williams ED and Williams GH: DNA replication licensing and human cell proliferation. J Cell Sci. 114:2027–2041. 2001.PubMed/NCBI

45 

Woodward AM, Göhler T, Luciani MG, Oehlmann M, Ge X, Gartner A, Jackson DA and Blow JJ: Excess Mcm2-7 license dormant origins of replication that can be used under conditions of replicative stress. J Cell Biol. 173:673–683. 2006. View Article : Google Scholar : PubMed/NCBI

46 

Hyrien O, Marheineke K and Goldar A: Paradoxes of eukaryotic DNA replication: MCM proteins and the random completion problem. Bioessays. 25:116–125. 2003. View Article : Google Scholar : PubMed/NCBI

47 

Masata M, Malínský J, Fidlerová H, Smirnov E and Raska I: Dynamics of replication foci in early S phase as visualized by cross-correlation function. J Struct Biol. 151:61–68. 2005. View Article : Google Scholar : PubMed/NCBI

48 

Kunnev D, Freeland A, Qin M, Leach RW, Wang J, Shenoy RM and Pruitt SC: Effect of minichromosome maintenance protein 2 deficiency on the locations of DNA replication origins. Genome Res. 25:558–569. 2015. View Article : Google Scholar : PubMed/NCBI

49 

Kwon HJ, Hong YK, Park C, Choi YH, Yun HJ, Lee EW and Kim BW: Widdrol induces cell cycle arrest, associated with MCM down-regulation, in human colon adenocarcinoma cells. Cancer Lett. 290:96–103. 2010. View Article : Google Scholar : PubMed/NCBI

50 

Minagawa Y, Kigawa J, Itamochi H, Kanamori Y, Shimada M, Takahashi M and Terakawa N: Cisplatin-resistant HeLa cells are resistant to apoptosis via p53-dependent and -independent pathways. Jpn J Cancer Res. 90:1373–1379. 1999. View Article : Google Scholar : PubMed/NCBI

51 

Asada N, Tsuchiya H and Tomita K: De novo deletions of p53 gene and wild-type p53 correlate with acquired cisplatin-resistance in human osteosarcoma OST cell line. Anticancer Res. 19:5131–5137. 1999.PubMed/NCBI

52 

Kigawa J, Sato S, Shimada M, Takahashi M, Itamochi H, Kanamori Y and Terakawa N: p53 gene status and chemosensitivity in ovarian cancer. Hum Cell. 14:165–171. 2001.PubMed/NCBI

Related Articles

Journal Cover

September 2019
Volume 20 Issue 3

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Deng, M., Sun, J., Xie, S., Zhen, H., Wang, Y., Zhong, A. ... Guo, L. (2019). Inhibition of MCM2 enhances the sensitivity of ovarian cancer cell to carboplatin. Molecular Medicine Reports, 20, 2258-2266. https://doi.org/10.3892/mmr.2019.10477
MLA
Deng, M., Sun, J., Xie, S., Zhen, H., Wang, Y., Zhong, A., Zhang, H., Lu, R., Guo, L."Inhibition of MCM2 enhances the sensitivity of ovarian cancer cell to carboplatin". Molecular Medicine Reports 20.3 (2019): 2258-2266.
Chicago
Deng, M., Sun, J., Xie, S., Zhen, H., Wang, Y., Zhong, A., Zhang, H., Lu, R., Guo, L."Inhibition of MCM2 enhances the sensitivity of ovarian cancer cell to carboplatin". Molecular Medicine Reports 20, no. 3 (2019): 2258-2266. https://doi.org/10.3892/mmr.2019.10477